The first FDA-approved MASH drug doesn’t treat patients with liver cirrhosis. A new Boehringer Ingelheim/Ochre Bio collaboration is researching regenerative medicines that could treat patients in this most advanced stage of the fatty liver disease.
The post Boehringer Ingelheim Strikes Regenerative Med R&D Deal Spanning MASH & More Liver Diseases appeared first on MedCity News.
